文献速递心外重症与机械循环支持

NHLBI REVIVE-IT 研究:在当前左心室辅助装置治疗背景下解读其中止原因

The NHLBI REVIVE-IT study: Understanding its discontinuation in the context of current left ventricular assist device therapy.
PubMed 文献 · J Heart Lung Transplant · 2016-10-06

美国国立卫生研究院心肺血液研究所于2008年3月召开工作组会议,讨论如何通过涉及左心室辅助装置(LVAD)的临床试验推进心衰治疗,并认为领域已准备好评估长期LVAD治疗用于病情较轻患者,由此产生了REVIVE-IT先导研究。REVIVE-IT旨在比较LVAD治疗与最佳药物治疗在病情较轻心衰患者中的效果,以确定永久LVAD更广泛应用是否与改善生存、生活质量或功能容量相关。尽管获得医学界、产业界和政府机构大力支持,REVIVE-IT未能达成目标,其失败原因具有启示意义,教训可能适用于未来病情较轻心衰人群的LVAD研究。

要点

  • REVIVE-IT旨在评估LVAD用于病情较轻心衰患者是否改善生存、生活质量或功能容量。
  • 该先导研究虽获多方支持,但未能完成目标,原因对后续研究有借鉴价值。
  • 未来在病情较轻心衰人群开展LVAD研究需吸取REVIVE-IT的经验教训。

核心结论

  • REVIVE-IT先导研究未能达成目标,其失败原因对未来病情较轻心衰患者的LVAD研究具有启示意义。

研究设计与样本

  • 美国国立卫生研究院心肺血液研究所于2008年3月召开工作组会议,讨论通过LVAD临床试验推进心衰治疗。
  • 由此产生REVIVE-IT先导研究,旨在比较LVAD治疗与最佳药物治疗在病情较轻心衰患者中的效果。

主要发现

  • REVIVE-IT旨在确定永久LVAD更广泛应用是否与改善生存、生活质量或功能容量相关。
  • 尽管获得医学界、产业界和政府机构大力支持,REVIVE-IT未能达成目标。

临床怎么用

  • 临床医生应了解REVIVE-IT未能完成,目前LVAD适应症仍限于现有指征,不应外推至病情较轻患者。

局限性

  • REVIVE-IT未能达成目标,无法提供LVAD用于病情较轻心衰患者的疗效与安全性随机数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The National Institutes of Health National Heart, Lung, and Blood Institute convened a working group in March 2008 to discuss how therapies for heart failure (HF) might be best advanced using clinical trials involving left ventricular assist devices (LVAD). This group opined that the field was ready for a trial to assess the use of long-term ventricular assist device therapy in patients who are less ill than patients currently eligible for destination therapy, which resulted in the Randomized Evaluation of VAD InterVEntion before Inotropic Therapy (REVIVE-IT) pilot study. The specific objective of REVIVE-IT was to compare LVAD therapy with optimal medical management in patients with less advanced HF than current LVAD indications to determine if wider application of permanent LVAD use to less ill patients would be associated with improved survival, quality of life, or functional capacity. REVIVE-IT represented an extraordinary effort to provide data from a randomized clinical trial to inform clinicians, scientists, industry, and regulatory agencies about the efficacy and safety of LVAD therapy in a population with less advanced HF. Despite significant support from the medical community, industry, and governmental agencies, REVIVE-IT failed to accomplish its goal. The reasons for its failure are instructive, and the lessons learned from the REVIVE-IT experience are likely to be relevant to any future study of LVAD therapy in a population with less advanced HF.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Pagani FD, Aaronson KD, Kormos R, et al. The NHLBI REVIVE-IT study: Understanding its discontinuation in the context of current left ventricular assist device therapy. J Heart Lung Transplant. 2016. PMID: 27836022. doi:10.1016/j.healun.2016.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。